Robbie Marcus
Stock Analyst at JP Morgan
(3.91)
# 622
Out of 5,138 analysts
177
Total ratings
55.17%
Success rate
9.19%
Average return
Main Sectors:
Stocks Rated by Robbie Marcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EW Edwards Lifesciences | Upgrades: Overweight | $90 → $100 | $84.49 | +18.36% | 7 | Dec 18, 2025 | |
| INSP Inspire Medical Systems | Maintains: Neutral | $82 → $118 | $96.47 | +22.32% | 8 | Dec 16, 2025 | |
| COO The Cooper Companies | Maintains: Neutral | $66 → $78 | $82.31 | -5.24% | 7 | Dec 5, 2025 | |
| MDT Medtronic | Maintains: Neutral | $90 → $100 | $99.00 | +1.01% | 12 | Nov 13, 2025 | |
| HTFL HeartFlow | Maintains: Overweight | $36 → $40 | $36.12 | +10.74% | 2 | Nov 13, 2025 | |
| CNMD CONMED | Maintains: Neutral | $58 → $52 | $42.55 | +22.21% | 8 | Nov 6, 2025 | |
| RXST RxSight | Maintains: Underweight | $8 → $9 | $9.79 | -8.07% | 6 | Nov 6, 2025 | |
| ZBH Zimmer Biomet Holdings | Downgrades: Neutral | $115 → $100 | $88.75 | +12.68% | 7 | Nov 6, 2025 | |
| CBLL CeriBell | Maintains: Overweight | $21 → $17 | $22.84 | -25.57% | 2 | Nov 5, 2025 | |
| DXCM DexCom | Maintains: Neutral | $90 → $75 | $69.24 | +8.32% | 3 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $12 → $13 | $12.65 | +2.77% | 7 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $16 | $17.44 | -8.26% | 3 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $16 | $17.34 | -7.73% | 5 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $15 → $7 | $5.47 | +27.97% | 7 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $120 | $80.35 | +49.35% | 1 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $36 | $20.37 | +76.73% | 17 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $445 | $362.49 | +22.76% | 9 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $575 → $675 | $541.34 | +24.69% | 5 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $12 → $13 | $7.99 | +62.70% | 3 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $110 | $90.03 | +22.18% | 13 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $330 | $286.49 | +15.19% | 4 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $40 | $41.46 | -3.52% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $82.51 | +9.08% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $53 → $50 | $24.26 | +106.10% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $8 | $2.65 | +201.89% | 2 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $284 → $250 | $350.49 | -28.67% | 9 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $7 | $6.45 | +8.53% | 13 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $125 → $118 | $123.53 | -4.48% | 5 | Oct 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $116 → $156 | $172.04 | -9.32% | 2 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $55 → $40 | $114.48 | -65.06% | 2 | May 5, 2020 |
Edwards Lifesciences
Dec 18, 2025
Upgrades: Overweight
Price Target: $90 → $100
Current: $84.49
Upside: +18.36%
Inspire Medical Systems
Dec 16, 2025
Maintains: Neutral
Price Target: $82 → $118
Current: $96.47
Upside: +22.32%
The Cooper Companies
Dec 5, 2025
Maintains: Neutral
Price Target: $66 → $78
Current: $82.31
Upside: -5.24%
Medtronic
Nov 13, 2025
Maintains: Neutral
Price Target: $90 → $100
Current: $99.00
Upside: +1.01%
HeartFlow
Nov 13, 2025
Maintains: Overweight
Price Target: $36 → $40
Current: $36.12
Upside: +10.74%
CONMED
Nov 6, 2025
Maintains: Neutral
Price Target: $58 → $52
Current: $42.55
Upside: +22.21%
RxSight
Nov 6, 2025
Maintains: Underweight
Price Target: $8 → $9
Current: $9.79
Upside: -8.07%
Zimmer Biomet Holdings
Nov 6, 2025
Downgrades: Neutral
Price Target: $115 → $100
Current: $88.75
Upside: +12.68%
CeriBell
Nov 5, 2025
Maintains: Overweight
Price Target: $21 → $17
Current: $22.84
Upside: -25.57%
DexCom
Oct 31, 2025
Maintains: Neutral
Price Target: $90 → $75
Current: $69.24
Upside: +8.32%
Oct 31, 2025
Maintains: Underweight
Price Target: $12 → $13
Current: $12.65
Upside: +2.77%
Oct 30, 2025
Maintains: Neutral
Price Target: $13 → $16
Current: $17.44
Upside: -8.26%
May 14, 2025
Maintains: Overweight
Price Target: $14 → $16
Current: $17.34
Upside: -7.73%
May 9, 2025
Downgrades: Underweight
Price Target: $15 → $7
Current: $5.47
Upside: +27.97%
Mar 28, 2025
Initiates: Overweight
Price Target: $120
Current: $80.35
Upside: +49.35%
Feb 21, 2025
Maintains: Neutral
Price Target: $38 → $36
Current: $20.37
Upside: +76.73%
Jan 29, 2025
Maintains: Overweight
Price Target: $420 → $445
Current: $362.49
Upside: +22.76%
Jan 24, 2025
Maintains: Overweight
Price Target: $575 → $675
Current: $541.34
Upside: +24.69%
Dec 17, 2024
Upgrades: Neutral
Price Target: $12 → $13
Current: $7.99
Upside: +62.70%
Dec 16, 2024
Maintains: Overweight
Price Target: $100 → $110
Current: $90.03
Upside: +22.18%
Dec 12, 2024
Maintains: Overweight
Price Target: $280 → $330
Current: $286.49
Upside: +15.19%
Oct 30, 2024
Maintains: Overweight
Price Target: $30 → $40
Current: $41.46
Upside: -3.52%
Sep 9, 2024
Initiates: Neutral
Price Target: $90
Current: $82.51
Upside: +9.08%
Aug 8, 2024
Maintains: Neutral
Price Target: $53 → $50
Current: $24.26
Upside: +106.10%
May 8, 2024
Downgrades: Neutral
Price Target: $15 → $8
Current: $2.65
Upside: +201.89%
Feb 23, 2024
Downgrades: Neutral
Price Target: $284 → $250
Current: $350.49
Upside: -28.67%
Nov 8, 2023
Maintains: Underweight
Price Target: $8 → $7
Current: $6.45
Upside: +8.53%
Oct 20, 2022
Maintains: Overweight
Price Target: $125 → $118
Current: $123.53
Upside: -4.48%
Jan 27, 2022
Maintains: Overweight
Price Target: $116 → $156
Current: $172.04
Upside: -9.32%
May 5, 2020
Maintains: Neutral
Price Target: $55 → $40
Current: $114.48
Upside: -65.06%